LL-37 is the only antimicrobial peptide of the cathelicidin family produced by humans, used experimentally to fight bacterial infections, accelerate wound healing, and modulate immune responses.
What it does
LL-37 is a 37-amino acid peptide released by immune and skin cells — neutrophils, macrophages, keratinocytes — when the body detects infection or tissue damage. Its defining structural feature is an amphipathic α-helix (a coiled shape with one water-attracting face and one fat-attracting face), which allows it to embed into bacterial cell membranes and punch pores through them, killing the cell within minutes. This works against gram-positive and gram-negative bacteria, many fungi, and enveloped viruses like influenza Haoran 2026. It also binds and neutralizes lipopolysaccharide (LPS) — the toxic fragment of gram-negative bacterial walls that triggers the runaway inflammatory cascade in sepsis Aldeen 2025.
Beyond direct killing, LL-37 acts as an immune traffic controller. It binds FPR2 (formyl peptide receptor 2) on immune cells, drawing neutrophils, monocytes, and T-cells to infection sites. It activates dendritic cells (the immune system's sentinels that coordinate the adaptive response), effectively bridging the fast, non-specific innate immune response with the slower, targeted adaptive response Fen 2025. Vitamin D directly upregulates LL-37 gene expression — this is one of the primary mechanisms linking vitamin D status to infection resistance NCT02278172.
In wounds, LL-37 transactivates EGFR (epidermal growth factor receptor) on keratinocytes (skin cells), driving them to migrate and divide across the wound bed. It also promotes angiogenesis (new blood vessel formation) at the repair site Madhawa 2025. One complication: LL-37 levels are abnormally elevated in psoriatic skin lesions and in rosacea, where it appears to drive inflammation rather than resolve it Rui 2026, which matters for both its clinical potential and its contraindication profile.
What the evidence shows
Bacterial infection and antimicrobial activity Strong mechanistic and in vitro evidence; limited direct human trial data
In cell and animal studies, LL-37 rapidly lyses a broad spectrum of pathogens including drug-resistant strains Jessica 2026. Synthetic analogues modeled on LL-37 have shown protection against E. coli-induced cell death in preclinical models Soumitra 2025. Against Klebsiella pneumoniae, related cathelicidins have been shown to disrupt established biofilms — structured bacterial colonies that are notoriously resistant to antibiotics L 2025. Importantly, some bacteria have evolved resistance mechanisms specifically targeting LL-37, which complicates its use as a standalone antimicrobial Jessica 2026. Human trials directly testing exogenous LL-37 for infection remain sparse.
Wound healing Moderate preclinical evidence; early human/clinical data emerging
LL-37 loaded into extracellular vesicles (nano-scale membrane packages that can carry and deliver molecules) significantly accelerated wound closure and antibacterial activity in preclinical models Madhawa 2025. The mechanism — EGFR transactivation driving keratinocyte migration — is well characterized. Human data is largely indirect; wound-healing applications are still in early development with no large randomized trials published.
Sepsis and endotoxin neutralization Strong mechanistic rationale; one registered human trial, results limited
LL-37 neutralizes LPS, the endotoxin fragment responsible for the cytokine storm in gram-negative sepsis. A registered trial (NCT03369275) explored cellular immunotherapy for septic shock in a context relevant to host defense peptides, but direct LL-37 administration in sepsis has not been tested in large human cohorts. The mechanistic case is strong; the clinical evidence is not yet there to match it Aldeen 2025.
Periodontal disease Early human trial data; ongoing investigation
A registered clinical trial (NCT04404335) examined LL-37 as a biomarker in periodontal treatment response, reflecting interest in its role in oral innate immunity. Research has also implicated dysregulated oral innate immunity — including cathelicidin pathways — in the link between periodontal pathogens and neuroinflammation E 2026. This remains an early-stage investigational area.
Rosacea and inflammatory skin conditions Moderate mechanistic evidence; LL-37 more likely a driver than a treatment here
In rosacea, abnormally processed forms of LL-37 appear to activate mast cells via a mitochondrial stress pathway (mtDNA/cGAS/STING signaling), amplifying skin inflammation rather than resolving it Rui 2026. This dual role — anti-infective in normal concentrations, pro-inflammatory when dysregulated — is one of the more important safety signals for anyone considering exogenous use.
How it's used
In studies and self-reported protocols, subcutaneous (subQ) doses range from 100 mcg twice weekly at the lower end to 500 mcg every other day at the higher end, with 200–400 mcg two to three times weekly representing the middle range. Nebulized and intranasal routes have also been explored for respiratory applications. The plasma half-life is approximately 30 minutes, which is short; timing relative to meals or activity does not appear to significantly affect outcomes. There is no established clinical dosing protocol approved by any regulatory body.
Side effects and safety
Reported side effects range from mild injection site reactions and local redness to localized inflammation and headache. The more serious concern is immune overactivation: LL-37 can trigger or worsen autoimmune flares, particularly in individuals with pre-existing inflammatory or autoimmune conditions. Its known role in psoriasis pathology — where endogenous LL-37 drives lesion inflammation Rui 2026 — makes exogenous use in psoriasis patients a relative contraindication. Pregnancy and known hypersensitivity are absolute contraindications. Long-term safety data from human use simply does not exist; the peptide's short half-life limits systemic accumulation, but chronic immune stimulation effects are unknown. The same mechanisms that make it useful against pathogens can, in excess, turn against host tissue.
Bottom line
LL-37 has a well-characterized mechanism and compelling preclinical data for infection control and wound healing, but human trial evidence remains thin and fragmented. It is most interesting as a research compound; people with autoimmune conditions, psoriasis, or rosacea have specific reasons to be cautious given its documented pro-inflammatory potential in those contexts.